NEW YORK – GenMark Diagnostics reported after the close of the market on Monday a 23 percent increase in second quarter revenues, driven by strong placements of its ePlex analyzer.
Separately, the company said in a filing with the US Securities and Exchange Commission that it has entered into an equity distribution agreement with Canaccord Genuity relating to shares of the diagnostic firm's common stock. Under the terms of the agreement, GenMark may offer and sell shares of its common stock having an aggregate value of up to $35 million at an offering price of $6.03 per share.